Table 2.
Clinical features of anti-MDA5 antibody positive DM patients
| Patient ID | ILD | Weakness | High CK | High Aldo | Arthritis | Fever | Raynauds | Calcinosis | Ulcerations | Mouth pain | Mechanic’s Hands | Gottron’s | Heliotrope | Palmar erythema | Medications* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM 1 | Y | Y | Y | U | Y | Y | Y | N | Y | Y | Y | Y | Y | N | MTX, Pred, MMF |
| DM 2 | Y | Y | Y | Y | Y | N | N | N | Y | N/A | N | Y | Y | U | MTX, Pred, HCQ |
| DM 3 | Y | N | N | N | Y | Y | N | N | N | N | Y | Y | N | N | MTX, Pred, AZA |
| DM 4 | N | Y | N | Y | Y | Y | N | N | Y | N | N | Y | Y | N | Pred, HCQ |
| DM 5 | Y | N | Y | Y | N | N | N | N | N | Y | Y | Y | Y | N | Pred, MMF, HCQ |
| DM 6 | Y | Y | N | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | MTX, MMF, Pred, Imuran |
| DM 7 | N | N | N | N | Y | N | Y | N | Y | N | Y | Y | Y | N | MTX, IVIG, HCQ |
| DM 8 | N | N | N | N | N | N | N | Y | Y | N | Y | Y | Y | N | MMF, Pred, IVIG, MTX |
| DM 9 | Y | Y | N | N | Y | N | Y | N | Y | Y | Y | Y | Y | Y | Pred, MMF, RTX, Imuran, IVIG |
| DM 10 | Y | N | N | Y | Y | N | N | Y | Y | N | Y | Y | Y | N | Pred, MMF, IVIG, MTX |
| DM 11 | Y | Y | Y | Y | Y | Y | Y | N | Y | Y | Y | Y | N | N | MMF, Pred, MTX, AZA, Tacro |
|
| |||||||||||||||
| Total %positive | 72.7 | 54.5 | 36.4 | 60 | 81.8 | 45.5 | 45.5 | 27.3 | 81.8 | 50 | 81.8 | 100 | 81.8 | 18.2 | |
Aldo = aldolase; AZA = azathioprine; HCQ = hydroxychloroquine; IVIG = intravenous immunoglobulin; MMF = mycophenylate mofetil; MTX = methotrexate; Pred = prednisone; RTX = rituximab;Tacro = tacrolimus
*
Medication use is indicated for the entire course of follow-up
Y = yes; N = no; U = unknown